Treatment-related mortality and overall survival outcomes of ALL patients treated with Hunger 1 and Hunger 2 regimens at BCCOE
| . | Hunger 1 end of therapy survival3 . | Hunger 2 end of delayed intensification survival* . |
|---|---|---|
| No. of patients starting induction phase | 40 | 17 |
| TRM (%) | 3 | 0 |
| Death as a result of disease (%) | 75 | 24 |
| Event-free survival (%) | 22 | —† |
| . | Hunger 1 end of therapy survival3 . | Hunger 2 end of delayed intensification survival* . |
|---|---|---|
| No. of patients starting induction phase | 40 | 17 |
| TRM (%) | 3 | 0 |
| Death as a result of disease (%) | 75 | 24 |
| Event-free survival (%) | 22 | —† |
Data for Hunger 2 from Dugan G. Implementation of the Hunger 2 Regimen for Acute Lymphoblastic Leukemia in the Butaro Cancer Center of Excellence: Toxicity and Interim Outcomes (unpublished master’s thesis). Kigali, Rwanda: University of Global Health Equity; 2018.
Sixty-five percent of patients in clinical remission at the end of delayed intensification.